Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Feb;111(2):533–538. doi: 10.1111/j.1476-5381.1994.tb14770.x

Radioligand binding studies of alpha 1-adrenoceptor subtypes in rat heart.

M C Michel 1, G Hanft 1, G Gross 1
PMCID: PMC1909949  PMID: 7911718

Abstract

1. In order to characterize the alpha 1-adrenoceptor subtypes mediating positive inotropic effects of adrenaline (in the presence of propranolol) in rat right ventricular strips and the Ca2+ sources used to elicit them, we have used radioligand binding to identify the alpha 1-adrenoceptor subtypes present in rat heart and the alpha 1-adrenoceptor affinity and subtype-selectivity of various pharmacological tools. 2. Amitryptiline, mianserin, trimipramine, oxaprotiline, clonidine, chloroethylclonidine, phenoxybenzamine, BE 2254 and 8-OH-DPAT competed for [3H]-prazosin binding in rat heart, vas deferens, liver, spleen, cerebral cortex and hippocampus but none of them displayed detectable alpha 1-adrenoceptor subtype-selectivity; nitrendipine did not compete for [3H]-prazosin binding in concentrations up to 5 mumol 1(-1). 3. The alpha 1 A-adrenoceptor-selective, 5-methyl-urapidil, (+)-niguldipine, and to a lesser extent (-)-niguldipine competed for [3H]-prazosin binding in rat heart, vas deferens, cerebral cortex and hippocampus with shallow and biphasic curves; analysis of these curves demonstrated that rat heart contains alpha 1A-and alpha 1B-adrenoceptors in a 20:80 ratio. 4. Treatment of rat right ventricular strips with 100 mumol l-1 chloroethylclonidine for 30 min at 30 degrees C followed by 60 min washout reduced the number of alpha 1-adrenoceptors, as assessed by [3H]-prazosin saturation experiments, by 74%. Treatment with 100 mumol l(-1) CdCl2 did not affect number or affinity of cardiac alpha 1-adrenoceptors and combined treatment with chlorethylclonidine and CdCl2 reduced alpha 1-adrenoceptor number by 90%.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
533

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benfey B. G. Function of myocardial alpha-adrenoceptors. Life Sci. 1990;46(11):743–757. doi: 10.1016/0024-3205(90)90062-v. [DOI] [PubMed] [Google Scholar]
  2. Boer R., Grassegger A., Schudt C., Glossmann H. (+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1989 May 11;172(2):131–145. doi: 10.1016/0922-4106(89)90004-7. [DOI] [PubMed] [Google Scholar]
  3. Bylund D. B. Subtypes of alpha 1- and alpha 2-adrenergic receptors. FASEB J. 1992 Feb 1;6(3):832–839. doi: 10.1096/fasebj.6.3.1346768. [DOI] [PubMed] [Google Scholar]
  4. Endoh M., Takanashi M., Norota I. Role of alpha 1A adrenoceptor subtype in production of the positive inotropic effect mediated via myocardial alpha 1 adrenoceptors in the rabbit papillary muscle: influence of selective alpha 1A subtype antagonists WB 4101 and 5-methylurapidil. Naunyn Schmiedebergs Arch Pharmacol. 1992 May;345(5):578–585. doi: 10.1007/BF00168952. [DOI] [PubMed] [Google Scholar]
  5. Gross G., Hanft G., Kolassa N. Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5-HT) binding sites of the 5-HT1A subtype and for alpha 1-adrenoceptor binding sites. Naunyn Schmiedebergs Arch Pharmacol. 1987 Dec;336(6):597–601. doi: 10.1007/BF00165749. [DOI] [PubMed] [Google Scholar]
  6. Gross G., Lues I. Thyroid-dependent alterations of myocardial adrenoceptors and adrenoceptor-mediated responses in the rat. Naunyn Schmiedebergs Arch Pharmacol. 1985 Jun;329(4):427–439. doi: 10.1007/BF00496378. [DOI] [PubMed] [Google Scholar]
  7. Han C. D., Minneman K. P. Interaction of subtype-selective antagonists with alpha 1-adrenergic receptor binding sites in rat tissues. Mol Pharmacol. 1991 Oct;40(4):531–538. [PubMed] [Google Scholar]
  8. Han C., Abel P. W., Minneman K. P. Heterogeneity of alpha 1-adrenergic receptors revealed by chlorethylclonidine. Mol Pharmacol. 1987 Oct;32(4):505–510. [PubMed] [Google Scholar]
  9. Hanft G., Gross G., Beckeringh J. J., Korstanje C. Alpha 1-adrenoceptors: the ability of various agonists and antagonists to discriminate between two distinct [3H]prazosin binding sites. J Pharm Pharmacol. 1989 Oct;41(10):714–716. doi: 10.1111/j.2042-7158.1989.tb06348.x. [DOI] [PubMed] [Google Scholar]
  10. Hanft G., Gross G. Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br J Pharmacol. 1989 Jul;97(3):691–700. doi: 10.1111/j.1476-5381.1989.tb12005.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hanft G., Gross G. The effect of reserpine, desipramine and thyroid hormone on alpha 1a- and alpha 1b-adrenoceptor binding sites: evidence for a subtype-specific regulation. Br J Clin Pharmacol. 1990;30 (Suppl 1):125S–127S. doi: 10.1111/j.1365-2125.1990.tb05482.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Johnson R. D., Minneman K. P. Differentiation of alpha 1-adrenergic receptors linked to phosphatidylinositol turnover and cyclic AMP accumulation in rat brain. Mol Pharmacol. 1987 Mar;31(3):239–246. [PubMed] [Google Scholar]
  13. Knowlton K. U., Michel M. C., Itani M., Shubeita H. E., Ishihara K., Brown J. H., Chien K. R. The alpha 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem. 1993 Jul 25;268(21):15374–15380. [PubMed] [Google Scholar]
  14. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  15. Lomasney J. W., Cotecchia S., Lefkowitz R. J., Caron M. G. Molecular biology of alpha-adrenergic receptors: implications for receptor classification and for structure-function relationships. Biochim Biophys Acta. 1991 Oct 26;1095(2):127–139. doi: 10.1016/0167-4889(91)90075-9. [DOI] [PubMed] [Google Scholar]
  16. Michel M. C., Hanft G., Gross G. Functional studies on alpha 1-adrenoceptor subtypes mediating inotropic effects in rat right ventricle. Br J Pharmacol. 1994 Feb;111(2):539–546. doi: 10.1111/j.1476-5381.1994.tb14771.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Michel M. C., Kanczik R., Khamssi M., Knorr A., Siegl H., Beckeringh J. J., Brodde O. E. Alpha and beta-adrenoceptors in hypertension. I. Cardiac and renal alpha 1-, beta 1-, and beta 2-adrenoceptors in rat models of acquired hypertension. J Cardiovasc Pharmacol. 1989 Mar;13(3):421–431. doi: 10.1097/00005344-198903000-00010. [DOI] [PubMed] [Google Scholar]
  18. Minneman K. P., Han C., Abel P. W. Comparison of alpha 1-adrenergic receptor subtypes distinguished by chlorethylclonidine and WB 4101. Mol Pharmacol. 1988 May;33(5):509–514. [PubMed] [Google Scholar]
  19. Parini A., Coupry I., Laude D., Diop L., Vincent M., Sassard J., Dausse J. P. Noradrenaline content and adrenergic receptors in kidney and heart of the prehypertensive and hypertensive Lyon rat strain. Am J Hypertens. 1988 Apr;1(2):140–145. doi: 10.1093/ajh/1.2.140. [DOI] [PubMed] [Google Scholar]
  20. Schwinn D. A., Page S. O., Middleton J. P., Lorenz W., Liggett S. B., Yamamoto K., Lapetina E. G., Caron M. G., Lefkowitz R. J., Cotecchia S. The alpha 1C-adrenergic receptor: characterization of signal transduction pathways and mammalian tissue heterogeneity. Mol Pharmacol. 1991 Nov;40(5):619–626. [PubMed] [Google Scholar]
  21. Takanashi M., Norota I., Endoh M. Potent inhibitory action of chlorethylclonidine on the positive inotropic effect and phosphoinositide hydrolysis mediated via myocardial alpha 1-adrenoceptors in the rabbit ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol. 1991 Jun;343(6):669–673. doi: 10.1007/BF00184301. [DOI] [PubMed] [Google Scholar]
  22. Tsujimoto G., Tsujimoto A., Suzuki E., Hashimoto K. Glycogen phosphorylase activation by two different alpha 1-adrenergic receptor subtypes: methoxamine selectively stimulates a putative alpha 1-adrenergic receptor subtype (alpha 1a) that couples with Ca2+ influx. Mol Pharmacol. 1989 Jul;36(1):166–176. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES